TMC Life Optimistic About Growth Through Partnerships In 2025
TMC Life Optimistic About Growth Through Partnerships In 2025
Acting group CEO, meanwhile, Dr Melvin Heng Jun Li, expressed strong optimism for FY2024/25.
TMC Life Sciences Bhd, a leading player in the healthcare industry, achieved significant growth in the financial year ending 30 June 2024 (FY2023/24), focusing on enhancing services for women and children to capitalise on the robust growth in FY2024/25, according to a press statement circulated by the company.
根據該公司發佈的新聞聲明，醫療保健行業的領先企業TMC Life Sciences Bhd在截至2024年6月30日的財政年度（FY2023/24）中實現了顯著增長，專注於加強對婦女和兒童的服務，以利用2024/25財年的強勁增長。
Profit before tax increased by 29% to RM52.6 million year-on-year for FY2023/24. In line with this positive performance and in conjunction with Celebrating Life for 30 years, the board of directors has recommended a final single-tier dividend of 0.4898 sen per ordinary share.
2023/24財年稅前利潤同比增長29％，達到5260萬令吉。董事會建議將每股普通股每股0.4898仙的最終單級股息與這一積極表現一致，並與Celebrating Life合作了30年。
During the group's 22nd Annual General Meeting (AGM) today, Chairman Y Bhg Datuk Sri Mohd Mokhtar bin Mohd Shariff highlighted the group's strong financial position, reporting RM188.6 million in cash and bank balances for FY2023/24, a 13% year-on-year increase. .
在今天的集團第22屆年度股東大會（AGM）上，董事長Y Bhg Datuk Sri Mohd Mokhtar bin Mohd Shariff強調了該集團強勁的財務狀況，報告稱，2023/24財年的現金和銀行餘額爲18860萬令吉，同比增長13％。
Acting group CEO, meanwhile, Dr Melvin Heng Jun Li, expressed strong optimism for FY2024/25.
同時，集團代理首席執行官李恒軍博士對2024/25財年表示強烈樂觀。
Key highlights from FY2023/24 include the successful partnership between Thomson Hospital Kota Damansara (Thomson) and OncoCare Medical Malaysia Sdn Bhd
2023/24 財年的主要亮點包括哥打白沙羅湯姆森醫院（湯姆森）與 OncoCare Medical Malaysia Sdn Bhd 之間的成功合作
This collaboration, established on Sept 5, 2024, enhances the Thomson's oncology offerings, showcasing TMCLS's dedication to advancing cancer care.
這項合作建立於2024年9月5日，旨在增強湯姆森的腫瘤學產品，展示了TMCLS對推進癌症治療的承諾。
Notably, Thomson made history in July 2023 by becoming the first hospital in Southeast Asia to administer the US-approved Spinraza for Spinal Muscular Atrophy. Additionally, the hospital also performed its first bowel atresia surgery on a premature infant in April 2024,
demonstrating a commitment to pioneering medical procedures.
值得注意的是，湯姆森在2023年7月創造了歷史，成爲東南亞第一家使用美國批准的脊髓性肌萎縮症Spinraza的醫院。此外，該醫院還於2024年4月對一名早產兒進行了首次腸道閉鎖手術，
表明了對開創性醫療程序的承諾。
Looking ahead, TMC Life is strategically poised to capitalise on growth opportunities in the region, driven by increased capacity at Thomson and a resurgence in the fertility business through TMC Fertility. Additionally, a promising uptick in medical tourism further
enhances the group's potential for success.
展望未來，在湯姆森產能增加以及TMC Fertility生育業務復甦的推動下，TMC Life已做好戰略準備，抓住該地區的增長機會。此外，醫療旅遊業有望進一步增長
增強了集團的成功潛力。
TMC Life is also committed to addressing climate change, with initiatives designed to achieve Net Zero by 2050. The group's dedication to sustainable practices aligns with its ongoing efforts to expand its footprint in the healthcare sector.
TMC Life還致力於應對氣候變化，其舉措旨在到2050年實現淨零排放。該集團對可持續實踐的承諾與其爲擴大其在醫療保健領域的足跡所做的持續努力相吻合。
譯文內容由第三人軟體翻譯。
